CME Presentations

Diabetic Kidney Disease



  • Ralph DeFronzo, MD

    Ralph DeFronzo, MD

    Ralph DeFronzo, MD

    Professor of Medicine

    Ralph DeFronzo, MD, is Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Deputy Director of the Texas Diabetes Institute. His major interests focus on the pathogenesis and treatment of type 2 diabetes mellitus and the central role of insulin resistance in the metabolic-cardiovascular cluster of disorders known collectively as the Insulin Resistance Syndrome. Dr. DeFronzo has received many national and international awards including the Banting Award from the ADA (2008), the Claude Bernard Award from the EASD (2008) and most recently, Dr. DeFronzo received the Hamm International Prize (2017). These awards represent the highest scientific achievement awards given by the American and European Diabetes Associations.
  • Katherine Tuttle, MD, FASN, FACP, FNKF

    Katherine Tuttle, MD, FASN, FACP, FNKF

    Katherine Tuttle, MD, FASN, FACP, FNKF

    Executive Director for Research

    Katherine Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Health Care, Co-Principal Investigator of the Institute of Translational Health Sciences and Professor of Medicine at the University of Washington. Dr. Tuttle’s research interests are in diabetes and chronic kidney disease. She has published over 250 original articles and served as Associate Editor for the Clinical Journal of the American Society of Nephrology and the American Journal of Kidney Disease. Dr. Tuttle served on the Board of Directors for the Kidney Health Initiative and has chaired working committees for organizations including the NIDDK/NIH, the National Kidney Foundation, the American Society of Nephrology, the International Society of Nephrology, and the American Diabetes Association.

CME Information

Global Logo PQH Logo
Diabetic Kidney Disease: New Ways Forward
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with KDIGO.


This activity is supported by an independent educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc and Eli Lilly and Company, & Merck, Sharp, & Dohme Corp, a subsidiary of Merck & Company, Inc.


This activity was released on August 2, 2022 and is valid until August 2, 2023. Requests for credit must be made no later than August 2, 2023.


The target audiences for the proposed HCP activity are US-based nephrologists, endocrinologists, diabetologists, primary care providers, diabetes educators, advanced practitioners, physician assistants, nurse practitioners, and nurses in endocrinology and nephrology practices, as well as other HCPs who care for people with diabetes or kidney disease.


While chronic kidney disease (CKD) remains mostly asymptomatic until it is well advanced, multiple guidelines stress the importance of consistent and early screening. Albuminuria and eGFR, considered together, are the mainstays for classification and staging of CKD and can help guide prognosis and management. In addition, several new agents are now available for the management of CKD, especially in relation to type 2 diabetes mellitus (T2DM), with even more options on the horizon.

Join a panel of nephrology and endocrinology experts for an in-depth look at the combined role of eGFR and albuminuria as a marker of disease, as prognostic factors, and as a measure of response to therapy. To ensure appropriate patients have access to breakthrough therapies, panelists will review the mechanisms of action and safety and efficacy profiles of new and emerging agents, including SGLT2 inhibitors and new-generation mineralocorticoid receptor antagonists.


After completing this activity, the participant should be better able to:
  • Describe the evolution of CKD and DKD into kidney failure and the biomarkers, eGFR and albuminuria, used for early diagnosis and prognosis of kidney disease
  • Evaluate current evidence-based guidelines for management of CKD in people with diabetes, implications for early screening and diagnosis, and measures of therapeutic response
  • Discuss the importance of controlling risk factors associated with CKD, including diabetes, hypertension, and other cardiovascular risks and comorbidities
  • Identify the place in care of new agents for the management of CKD, including SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists, some of which may attenuate the need for multiple drug regimens


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Dr. Ralph DeFronzo
Professor of Medicine
Chief, Diabetes Division
UT Health San Antonio
Deputy Director
Texas Diabetes Institute
Consulting Fee (e.g., Advisory Board): Astra Zeneca, Novo-Nordisk, Boehringer-Ingelheim, Intarcia
Speakers Bureau: Astra Zeneca
Research Support: Boehringer-Ingelheim, Astra Zeneca, Merck
Dr. Katherine Tuttle
Executive Director for Research
Providence Health Care
Professor of Medicine, Division of Nephrology
Co-Principle Investigator Institute of Translational
Providence Health Care
University of Washington
Consulting Fee (e.g., Advisory Board): Eli Lilly, Boehringer Ingelheim, Astra Zeneca, Gilead, Goldfinch Bio, Novo Nordisk, Travere
Honoraria: Eli Lilly & Company, Astra Zeneca, Gilead, Goldfinch Bio, Bayer, Travere
Speakers Bureau: Eli Lilly & Company, Astra Zeneca, Gilead, Goldfinch Bio, Bayer

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner Reported Financial Relationship
Rhys Williams, MSN, FNP-C, RN Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel Nothing to disclose
Colleen Hefner Nothing to disclose
Caroline Laurendeau Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:

For any technical issues or issues with your CME Certificate, please contact DiabetesSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.